The invention refers to novel compositions with at least one prehormone, hormone from group consisting of mevalonate derivatives or from the group consisting of peptides and/or proteohormones and at least one mineral, constituent by preference iodine, selen and at least one Ginkgoloide against alkyl-acyl-GPC (AAGPC), its derivatives (alkyllipids) and/or products (e.g. acetylacyl-CoA). These new hormonal compositions are manufactured with at least one Ginkgoloide and/or acetylcysteine for oral, dietary, oily or local, cosmetic administration. Novel cosmetic preparations without addition of ether/volatile oils contain Ginkgoloides with at least one sun screening agent against impairments of pigmentation. The novel compositions are manufactured with prehormones and constituents to protect against alkylacyl-like destabilization of cells by preference under the conditions of critical lifestyle, critical morning urine samples and/or hypersensitivity syndromes.

A drug delivery system configured to be inserted transvaginally. The drug delivery system includes an outer skin defining a reservoir, and a mixture of a carrier oil and one or more cannabinoids inside the reservoir. The outer skin of the drug delivery device is permeable to the mixture of the carrier oil and the one or more cannabinoids. The drug delivery device may be a resilient ring, and the one or more cannabinoids may include Cannabidiol and less than approximately 0.03% Tetrahydrocannabinol.

A drug delivery system configured to be inserted transvaginally. The drug delivery system includes an outer skin defining a reservoir, and a mixture of a carrier oil and one or more cannabinoids inside the reservoir. The outer skin of the drug delivery device is permeable to the mixture of the carrier oil and the one or more cannabinoids. The drug delivery device may be a resilient ring, and the one or more cannabinoids may include Cannabidiol and less than approximately 0.03% Tetrahydrocannabinol.

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

A drug delivery system configured to be inserted transvaginally. The drug delivery system includes a core and a skin covering the core. The thermoplastic polymer core includes a mixture of a carrier oil and one or more cannabinoids, and the skin is permeable to the mixture of the carrier oil and the one or more cannabinoids. The drug delivery system may be a resilient ring.

A drug delivery system configured to be inserted transvaginally. The drug delivery system includes a core and a skin covering the core. The thermoplastic polymer core includes a mixture of a carrier oil and one or more cannabinoids, and the skin is permeable to the mixture of the carrier oil and the one or more cannabinoids. The drug delivery system may be a resilient ring.

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.